JP2017531646A5 - - Google Patents

Download PDF

Info

Publication number
JP2017531646A5
JP2017531646A5 JP2017518070A JP2017518070A JP2017531646A5 JP 2017531646 A5 JP2017531646 A5 JP 2017531646A5 JP 2017518070 A JP2017518070 A JP 2017518070A JP 2017518070 A JP2017518070 A JP 2017518070A JP 2017531646 A5 JP2017531646 A5 JP 2017531646A5
Authority
JP
Japan
Prior art keywords
hal
cor
conr
independently
atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017518070A
Other languages
English (en)
Japanese (ja)
Other versions
JP6662865B2 (ja
JP2017531646A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/001973 external-priority patent/WO2016050358A1/en
Publication of JP2017531646A publication Critical patent/JP2017531646A/ja
Publication of JP2017531646A5 publication Critical patent/JP2017531646A5/ja
Application granted granted Critical
Publication of JP6662865B2 publication Critical patent/JP6662865B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017518070A 2014-10-01 2015-10-01 ボロン酸誘導体 Active JP6662865B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14003389.5 2014-10-01
EP14003389 2014-10-01
PCT/EP2015/001973 WO2016050358A1 (en) 2014-10-01 2015-10-01 Boronic acid derivatives

Publications (3)

Publication Number Publication Date
JP2017531646A JP2017531646A (ja) 2017-10-26
JP2017531646A5 true JP2017531646A5 (enExample) 2019-10-17
JP6662865B2 JP6662865B2 (ja) 2020-03-11

Family

ID=51751859

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017518070A Active JP6662865B2 (ja) 2014-10-01 2015-10-01 ボロン酸誘導体

Country Status (21)

Country Link
US (1) US10669289B2 (enExample)
EP (1) EP3201206B1 (enExample)
JP (1) JP6662865B2 (enExample)
KR (1) KR102457840B1 (enExample)
CN (1) CN107001391B (enExample)
AU (1) AU2015327345B9 (enExample)
BR (1) BR112017006622A2 (enExample)
CA (1) CA2963203A1 (enExample)
CL (1) CL2017000792A1 (enExample)
DK (1) DK3201206T3 (enExample)
ES (1) ES2761774T3 (enExample)
IL (1) IL251302B (enExample)
MX (1) MX372823B (enExample)
MY (1) MY186911A (enExample)
NZ (1) NZ730981A (enExample)
PH (1) PH12017500293A1 (enExample)
RU (1) RU2717558C2 (enExample)
SG (1) SG11201702628XA (enExample)
UA (1) UA122672C2 (enExample)
WO (1) WO2016050358A1 (enExample)
ZA (1) ZA201703007B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10640520B2 (en) 2014-10-01 2020-05-05 Merck Patent Gmbh Boronic acid derivatives
EP3201207B1 (en) 2014-10-01 2021-02-24 Merck Patent GmbH Boronic acid derivatives
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
EP3201208B1 (en) 2014-10-01 2021-03-24 Merck Patent GmbH Boronic acid derivatives
HUE054460T2 (hu) * 2017-01-18 2021-09-28 Principia Biopharma Inc Immunproteaszóma-gátlók
IL272806B2 (en) * 2017-08-24 2023-09-01 Merck Patent Gmbh The history of boronic acid, its preparation and pharmaceutical preparations containing it
CN111065619B (zh) * 2017-08-29 2022-08-12 浙江海正药业股份有限公司 (E)-α,β-不饱和酰胺化合物及其制备方法和用途
US10807951B2 (en) * 2017-10-13 2020-10-20 The Regents Of The University Of California mTORC1 modulators
WO2019099582A1 (en) * 2017-11-16 2019-05-23 Principia Biopharma Inc. Immunoproteasome inhibitors
PL3710457T3 (pl) 2017-11-16 2023-02-20 Principia Biopharma Inc. Inhibitory immunoproteasomu
MX2021000214A (es) * 2018-07-26 2021-03-31 Merck Patent Gmbh Derivados de acido boronico.
CN113135943A (zh) * 2020-01-19 2021-07-20 首药控股(北京)有限公司 硼酸衍生物
CN113135944A (zh) * 2020-01-19 2021-07-20 首药控股(北京)有限公司 硼酸衍生物
US20240287102A1 (en) 2021-07-29 2024-08-29 Merck Patent Gmbh Novel crystalline forms of [(1r)-2-(1-benzofuran-3-yl)-1-{[(1s,2r,4r)-7-oxabicyclo[2.2.1]heptan-2-yl]formamido}ethyl]boronic acid, adducts thereof, and processes to obtain
JP7734276B2 (ja) * 2021-10-14 2025-09-04 ショウヤオ ホールディングス(ベイジン) カンパニー, リミテッド ボロン酸誘導体
WO2023232830A1 (en) 2022-06-02 2023-12-07 Merck Patent Gmbh Boronic acid adducts

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658885A (en) * 1993-04-27 1997-08-19 The Dupont Merck Pharmaceutical Company Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes
US5462964A (en) * 1993-10-20 1995-10-31 The Du Pont Merck Pharmaceutical Company Dipeptide boronic acid inhibitors of trypsin-like enzymes
IL111175A0 (en) * 1993-10-07 1994-12-29 Du Pont Merck Pharma Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them
WO2001002424A2 (en) * 1999-07-07 2001-01-11 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
DE60305113T2 (de) * 2002-09-09 2006-12-07 Trigen Ltd. Borsäuresalze und deren Verwendung in der Bereitstellung von Medikamente für die Thrombosebehandlung
US7576206B2 (en) * 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
TWI345465B (en) * 2003-08-14 2011-07-21 Cephalon Inc Proteasome inhibitors and methods of using the same
AR075090A1 (es) * 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
EP2560978B1 (en) * 2010-04-22 2019-01-30 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
SG10201605152SA (en) * 2011-12-22 2016-08-30 Ares Trading Sa Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
JP6505727B2 (ja) 2014-01-31 2019-04-24 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company ヘテロ環式p2’基を有する第xia因子阻害剤としてのマクロ環
EP3201208B1 (en) 2014-10-01 2021-03-24 Merck Patent GmbH Boronic acid derivatives
EP3201207B1 (en) 2014-10-01 2021-02-24 Merck Patent GmbH Boronic acid derivatives
US10640520B2 (en) 2014-10-01 2020-05-05 Merck Patent Gmbh Boronic acid derivatives
NO2721243T3 (enExample) 2014-10-01 2018-10-20
BR112017006708A2 (pt) 2014-10-01 2017-12-26 Janssen Pharmaceuticals Inc indóis mono- ou dissubstituídos como inibidores da replicação viral de dengue
US9944598B2 (en) 2014-10-01 2018-04-17 Janssen Pharmaceuticals, Inc. Mono- or di-substituted indole derivatives as dengue viral replication inhibitors

Similar Documents

Publication Publication Date Title
JP2018502048A5 (enExample)
JP2017536335A5 (enExample)
AR122783A2 (es) Inhibidores de kras g12c y métodos para su uso
AR104963A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
ECSP22018571A (es) Degradadores bifuncionales de brd9 y sus métodos de uso
MX380928B (es) Inhibidores de kras g12c.
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
CO2018004800A2 (es) Antagonistas del receptor muscarinico 4 y metodos de uso.
CY1123451T1 (el) Αγωνιστες τριαζολης του υποδοχεα αρj
CO2020000194A2 (es) Inhibidores de quinasa alk2 que contienen imidazol
JP2016515561A5 (enExample)
CL2019002150A1 (es) Derivados de 3-fenil-4-amino-imidazo[4,5-c]piridin-2-ona y 7-fenil-6-amino-purin-8-ona sustituidos, inhibidores de tirosinacinasas, en particular tirosinacinasa de bruton (btk); composiciones que contiene los compuestos; y uso para enfermedades tales como cáncer, autoinmunitarias, inflamatorias y tromboembólicas. (divisional solicitud 201703073)
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
CY1124680T1 (el) Παραγωγα 8-[6-[3-(αμινο)προποξυ]-3-πυριδυλο]-1-ισοπροπυλο-ιμιδαζο[4,5-c]κινολιν-2-ονης ως εκλεκτiκοι ρυθμιστες κινασης μεταλλαγμενης αταξιας τελαγγειεκτασιας (atm) για τη θεραπευτικη αγωγη του καρκινου
WO2017205536A3 (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
CY1119771T1 (el) Ενωσεις αμινοπυριμιδινυλιου ως αναστολεις toy jak
MX2019013954A (es) Inhibidores covalentes de kras.
AR088748A1 (es) Macrociclos como inhibidores del factor xia
AR117189A1 (es) Derivados de 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activos contra el virus de la hepatitis b (vhb)
AR099228A1 (es) Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
MX383051B (es) Compuestos que inhiben eif4a y métodos relacionados a los mismos.
AR113826A1 (es) Indol-2-carboxamidas sustituidas con amino-tiazol activas contra el virus de la hepatitis b (vhb)
CO2018011408A2 (es) Compuestos de pirimidina como inhibidores de la quinasa jak
EA201991884A3 (ru) Ингибиторы g12c kras
AR102094A1 (es) Inhibidores de proteínas kras con una mutación g12c